ROS1 and lung carcinoma: Therefore, Lin and co-authors studied mechanisms of resistance to crizotinib and lorlatinib in ROS1 fusion-positive lung cancer by structural modeling and comparison of wild and mutated 3D structures of ROS1 (ROS proto-oncogene 1, receptor tyrosine kinase) [7].